News & Publications

News & Publications

Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC at ASCO 2017 Genitourinary Cancers Symposium

Data show robust degradation of androgen receptor in vitro and in vivo

NEW HAVEN, Conn., February 17, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced the presentation of new preclinical data on its oral androgen receptor (AR) PROTAC during a poster session at the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium (ASCO GU) in Orlando, FL.

“The new data presented today continue to validate our platform and the potential of PROTACs to drive durable and robust responses in important indications like castrate-resistant prostate cancer where inhibition can be effective yet short-lived,” noted Dr. John Houston, Ph.D., President of Research and Development and Chief Scientific Officer of Arvinas. “We continue to see the importance of orally bioavailable agents in hormone-driven cancers and are working to further advance both our oral AR and oral ER PROTACs towards the clinic.”

The poster titled, “An oral androgen receptor PROTAC degrader for prostate cancer” (abstract 179448) presents data from in vitro and in vivo studies of prostate cancer cell lines treated with a small molecule AR PROTAC that simultaneously binds E3-ubiquitin ligase and AR. The results show robust and durable degradation of all clinically relevant mutant AR proteins, including 92-98% degradation of total AR across all cell lines, suppression of prostate-specific antigen gene expression, inhibition of cell proliferation and the inducing of apoptosis of prostate cancer cell lines.

Regulating the androgen receptor signaling is an important factor in controlling progression in prostate cancer, but currently, standard of care androgen receptor inhibitors like enzalumtamide (Xtandi®) have shown limited efficacy because increased androgen production, increased expression of the androgen receptor and specific mutations of the receptor can overcome inhibition. Arvinas’ approach focuses on degrading the androgen receptor, resulting in its elimination. In contrast to traditional target inhibition, which is a competitive process, degradation is progressive and therefore less susceptible to increases in endogenous ligand, target expression, or mutations in the target.

Abstracts are available on the Arvinas website under Publications at www.arvinas.com.

About Arvinas

Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins. Based on groundbreaking research conducted at Yale University by Founder and Chief Scientific Advisor, Dr. Craig Crews, the company is translating innovative protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The company’s new PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets. For more information, visit www.arvinas.com.

 

CONTACT:

Arvinas Media Contact

Carolyn Hawley

carolyn@canalecomm.com

619-849-5382

 

Arvinas Investor Contact

Beth DelGiacco

Beth@SternIR.com

212-362-1200

 

Click to download PDF